The developing landscape of diabetes care is seeing a significant shift, driven by new incretin-based therapies. Presently, semaglutide has secured considerable traction, but emerging medications like tirzepatide, retatrutide, and cagrilintide are ready to alter the outlook. Tirzepatide, a dual G